Ottimo Pharma
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Innovation House Ramsgate Rd, Sandwich, ...Website
www.ottimopharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Ottimo Pharma
Ottimo Pharma is a private biotechnology company, co-founded in 2020 by Medicxi and Jonny Finlay, focused on the development of pioneering innovative cancer therapies for solid tumors. The Company's lead asset, Jankistomig, is a PD1/VEGFR2 bifunctional antibody designed as a dual pathway, biparatopic single-agent IgG therapy, targeting both immune checkpoint inhibition and angiogenesis in the treatment of cancer. By advancing this dual-pathway approach, Ottimo aims to offer a wider therapeutic window, improve cancer treatment outcomes and reduce the overall healthcare burden.Explore more
Ottimo Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ottimo Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Ottimo Pharma has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Ottimo Pharma recently announced quarterly report
Product Launch: Get notified when Ottimo Pharma launches new products
Click to see if Ottimo Pharma had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check out if Ottimo Pharma is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Ottimo Pharma has new funding data
Congratulate Masked Content for being promoted to Masked Content at Ottimo Pharma
Ottimo Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Ottimo Pharma as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Ottimo Pharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Ottimo Pharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Ottimo Pharma.
Ottimo Pharma financials insights
Gather financial insights about Ottimo Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Other Financing Round
$140M
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Product Development, Legal Affairs, Medical Research, Pharmaceuticals, Regulations
Funding
Funding
Funding
Ottimo Pharma News & Media
Lotte Biologics signs antibody drug CMO deal with UK's Ottimo Pharma - KED Global
BOSTON – Lotte Biologics Co. has signed a deal to manufacture an antibody therapy for British biotech startup Ottimo Pharma as the South Korean biopharmaOttimo Pharma Strengthens Board with Appointment of Roger Dansey, M.D. to its Board of Directors
Ottimo Pharma Strengthens Board with Appointment of Roger Dansey, M.D. to its Board of Directors.
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Ottimo Pharma
Sign Up For FreeTo access detailed company insights
Ottimo Pharma is a private biotechnology company, co-founded in 2020 by Medicxi and Jonny Finlay, focused on the development of pioneering innovative cancer therapies for solid tumors. The Company's lead asset, Jankistomig, is a PD1/VEGFR2 bifunctional antibody designed as a dual pathway, biparatopic single-agent IgG therapy, targeting both immune... Read More
